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Abstract
Eumycetoma is a morbid chronic granulomatous subcutaneous fungal disease. Despite high environmental exposure to this
fungus in certain regions of the world, only few develop eumycetoma for yet unknown reasons. Animal studies suggest that
co-infections skewing the immune system to a Th2-type response enhance eumycetoma susceptibility. Since chronic
schistosomiasis results in a strong Th2-type response and since endemic areas for eumycetoma and schistosomiasis do
regionally overlap, we performed a serological case-control study to identify an association between eumycetoma and
schistosomiasis. Compared to endemic controls, eumycetoma patients were significantly more often sero-positive for
schistosomiasis (p = 0.03; odds ratio 3.2, 95% CI 1.18–8.46), but not for toxoplasmosis, an infection inducing a Th1-type
response (p = 0.6; odds ratio 1.5, 95% CI 0.58–3.83). Here, we show that schistosomiasis is correlated to susceptibility for a
fungal disease for the first time.
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Introduction
Eumycetoma is a chronic granulomatous subcutaneous infec-
tious disease endemic in many tropical and sub-tropical regions in
the so-called mycetoma belt between 30uN and 15uS of the
equator [1]. Sudan is a country with the highest country-wide
prevalence of eumycetoma (Figure 1). In a recent survey con-
ducted by the Mycetoma Research Centre, it appeared that in the
endemic villages in the Gezira area of Sudan 2% of the population
has eumycetoma (Prof. A. Fahal, personal communication) [2,3].
Although mycetoma can be caused by a variety of bacterial and
fungal micro-organisms, most mycetoma cases in Sudan (ca. 70%)
are caused by the fungus Madurella mycetomatis (eumycetoma) [4].
Based on antibody measurements in earlier studies it was noted
that although most people living in endemic areas in the Sudan
have developed antibodies against M. mycetomatis, and thus have
been exposed to M. mycetomatis, only few of them actually
developed eumycetoma [5,6]. To date, it is unknown why some
people are predisposed to develop eumycetoma.
Multiple explanations can be considered for the scanty suscep-
tibility to eumycetoma. Firstly, genetic differences in the pathogen
might exist that could lead to pathogenic and non-pathogenic
variants of M. mycetomatis. Secondly, genetic polymorphisms in the
host involved in sex hormone synthesis and neutrophil function
have already been associated with eumycetoma, indicating that the
genetic make-up of the host is a crucial factor in susceptibility to
eumycetoma development [7–9]. Furthermore, a combination of
specific genetic requirements and capabilities in both the pathogen
and the host could lead to an even more sporadic development of
eumycetoma. Thirdly, temporal conditions influencing the host
immune response, such as co-infections, nutritional status, use of
antibiotics and/or immune suppression or skewing may also play a
role in susceptibility to M. mycetomatis. This possibility is supported
by the observation that M. mycetomatis could only induce eumy-
cetoma in animals in the presence of an adjuvant predisposing
towards a Th2-response [10] but not a Th1-response [11,12].
Skewing of the immune response is highly affected by invasive
pathogens [13], and therefore, co-infections could play a critical
role in eumycetoma [14]. In this respect, infections inducing a
strong and long-lasting Th2-type of immune response could favour
the development of eumycetoma disease most. Schistosomiasis
seems to meet such requirements for the following reasons. Firstly,
schistosomiasis induces a long-lasting Th2-type immune response
that is strong enough to even convert an already established Th1-
response [15,16]. Secondly, in endemic countries schistosomiasis is
often a chronic life-long disease. Even when patients are regularly
treated for schistosomiasis, their continuous exposure to the para-
site during fresh water contacts and the lack of the development of
immunity against schistosomes will rapidly result in a re-infection
with a persistent Th2-response.
Based upon the above mentioned observations, and the fact that
we recently have shown that eumycetoma patients have increased
concentrations of circulating IL-10 [7], we hypothesize that
schistosomiasis, which induces a Th2-type response with elevated
levels of IL-10, might increase the susceptibility to eumycetoma,
whereas toxoplasmosis which induces a Th1-type response
[16,17], should not be associated with eumycetoma.
Methods
Study population
A total of 84 serum samples was taken from 53 eumycetoma
patients and 31 controls, matched for age and gender, in the
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endemic areas of Sudan between 2001 and 2008 (Table 1). Serum
samples were stored at 280uC until assay. The patients’ demo-
graphic characteristics were recorded and that included gender,
duration of disease, lesion size and site of infection. Eumycetoma
was confirmed by culture and molecular identification based on
sequencing the Internal Transcribed Spacer [18]. Written
informed consent was obtained from all participants and ethical
clearance was obtained from Soba University Hospital Ethical
Committee, Khartoum, Sudan.
Serological response towards antigens of Toxoplasma,
Schistosoma and Madurella spp
Specific IgG antibodies against Toxoplasma gondii were deter-
mined with the commercially available Toxo IgG II assay on the
automated Liaison serology platform according to the manufac-
turer’s protocol (Diasorin, Saluggia, Italy). Antibody levels against
Schistosoma species were determined as described before by a
combination of a commercial indirect hemagglutination test with
Schistosoma mansoni adult worm antigens (IHA; Fumouze Labora-
tories, Levallois-Perret Cedex, France) and an enzyme-linked
immunosorbent assay with homemade S. mansoni Soluble Egg
Antigens (SEA) [19]. The IHA was considered positive when the
titre was $1:80 and the SEA ELISA was considered positive when
the Optical Density (O.D.) at 492 nm was $0.15. For optimal
specificity, Schistosoma spp. serology was only considered positive
when a positive result was obtained in both the IHA and SEA-
ELISA tests.
Antibody levels against Madurella mycetomatis Translationally
Controlled Tumour Protein (TCTP) were measured with Luminex
Technology as described before [5].
Statistical analysis
Difference in positive and negative serology for schistosomiasis
and toxoplasmosis between eumycetoma patients and endemic
controls were calculated with the Chi square test (GraphPad Instat
3.00) by determining both the two-sided p-value and the Odds
Ratio using Yates correction. The 95% confidence interval of the
Odds Ratio was calculated using the approximation of Woolf. The
Mann-Whitney U test was used to compare differences between
IgG levels raised against the MmTCTP antigen in the study
populations (GraphPad Instat 3.00). The Kruskal-Wallis test
(SPSS Inc 17) was used to test if concentrations of antibodies
against Schistosoma spp. differed significantly between patients with
larger lesions compared to patients with smaller lesions, by
including size (small, moderate, large) as the grouping variable. A
value of p,0.05 was considered significant.
Results
Between 2001 and 2008, 53 patients and 31 endemic controls
were included in the study. Most patients were male and had
eumycetoma of the foot (Table 1). All patients and controls came
from the same area mainly from Central Sudan as indicated in
Figure 1.
As shown in Figure 2, eumycetoma patients were significantly
more often sero-positive for Schistosoma infections as compared to
endemic controls (Chi square, p = 0.03). In other words, an
association exists between the infections caused by Madurella
mycetomatis and Schistosoma spp. since the odds ratio for co-occurring
schistosomiasis in eumycetoma patients is 3.2 (95% Confidence
Interval 1.18–8.46). In contrast, eumycetoma patients were not
significantly more often sero-positive for Toxoplasma gondii infec-
tions (Figure 2, Chi square, p = 0.5) thus the risk for developing
eumycetoma does not seem to be increased in case of concurrent
toxoplasmosis (Odds ratio 1.5, 95% Confidence Interval: 0.60–
3.75). No correlation was found between sero-positivity for
schistosomiasis and sero-positivity for toxoplasmosis (Chi square,
p = 0.1, Odds ratio 0.44, 95% Confidence Interval: 0.14–1.32).
Positive serology for either schistosomiasis or toxoplasmosis was
not correlated to the size of the eumycetoma lesion (Chi square,
p = 0.8 and p= 0.2, respectively, data not shown). Since schisto-
somiasis is known to reduce the humoral immune response against
co-infecting pathogens [20,21], we investigated the antibody
response against M. mycetomatis antigen TCTP. The antibody
levels against TCTP did not differ between the eumycetoma
patients with positive schistosomiasis serology and those with
negative schistosomiasis serology, nor did they differ between
matched endemic controls with positive schistosomiasis serology
and healthy endemic controls with negative schistosomiasis
serology (Figure 3). This suggests that schistosomiasis does not
influence the humoral immune response against the TCTP
antigen of M. mycetomatis.
Figure 1. Endemic regions of mycetoma, Schistosoma haemato-
mium and Schistosoma mansoni in Sudan. The area from which our
sera were collected is encircled. The cities of Khartoum, New Halfa and
Kassala are indicated.
doi:10.1371/journal.pntd.0002241.g001
Author Summary
Eumycetoma is a mutilating fungal disease of mainly the
foot and is found in (sub)tropical regions such as Sudan. At
the moment it is not understood why some people
develop eumycetoma and others not. In the regions were
eumycetoma is prevalent many other infections are also
found. These infections could alter the immune system
which makes people more or less susceptible in obtaining
another infection. One of the infections with such an effect
is Schistosomiasis. In Africa, eumycetoma is found in
regions were schistosomiasis is prevalent. In this study we
show that eumycetoma patients more often have anti-
bodies against Schistosoma species, than healthy controls
from the same region. In contrast, eumycetoma patients
did not have more often antibodies against Toxoplasma
species. This might implicate that schistosomiasis predis-
poses eumycetoma development. If schistosomiasis in-
deed predisposes eumycetoma development, eradicating
Schistosoma in a population could also lower the number
of eumycetoma cases in that area, which in the end could
lead to intervention strategies not only for schistosomiasis
but also for eumycetoma.
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Discussion
Schistosomiasis is a chronic disease with an estimated 200
million people infected in subtropical countries [22]. Therefore,
almost all schistosomiasis patients will subsequently be infected by
one or more additional pathogens. Although a prior infection with
schistosomes often has an effect on the subsequent infection by a
virus, bacterium, protozoan or other helminth, schistosomiasis can
cause both an increase or a decrease in the severity of the
subsequent infection for yet unknown reasons (reviewed in Abruzzi
and Fried [23]. Decreased subsequent disease severity was
observed for co-infections with Helicobacter pylori, Fasciola hepatica,
Echinostoma and with Plasmodium in case of S. haematobium schis-
tosomiasis [23]. In addition, a worsened outcome of a subsequent
co-infection has been described for HIV (reduced viral clearance)
[24], Leishmania donovani [25], Toxoplasma gondii, Entamoeba histolytica
infections and Plasmodium in case of S. mansoni schistosomiasis
[23,26]. The effect of subsequent fungal infections has not been
addressed yet.
Since eumycetoma infections can only be established in animals
with adjuvants inducing a strong Th2-type immune response, we
hypothesized that co-infections inducing a Th2-type immune
response would predispose to eumycetoma disease. This study
compared eumycetoma patients with matched endemic controls
without eumycetoma for co-infections with Schistosoma spp.. As a
control, Toxoplasma gondii infections were monitored since this
infection is also endemic in Sudan and results in a Th1-type of
immune response in immune-competent hosts [17].
Although we only studied a limited number of people, which
might not represent the full population of the study area, we did
Table 1. Details of the study population.
Eumycetoma patients
Healthy endemic
controls p-value
Number (n) 53 31
Gender (male/female) 51/2 30/1 p = 1.00**
Mean age years (range) 25.8 (13–74) 28.1 (20–47) p = 0.30***
Eumycetoma duration in years (range) 6.3 (1–15) NA*
Lesion site Foot NA
Lesion size (n) Large 18 NA
Medium 19 NA
Small 16 NA
Causative agent M. mycetomatis NA
Schistosoma serology**** Positive (n) 30 9 p= 0.03**
Negative (n) 19 18
Toxoplasma serology Positive (n) 24 11 p= 0.5**
Negative (n) 29 20
*NA: not applicable.
**Chi square.
***Mann-Whitney.
****4 patients and 4 controls had an equivocal outcome after multiple testing, they were left out of the analysis.
doi:10.1371/journal.pntd.0002241.t001
Figure 2. Percentage of eumycetoma patients and matched controls with positive serology for schistosomiasis and toxoplasmosis.
Percentage of eumycetoma patients and matched controls with positive serology for schistosomiasis (panel A) and toxoplasmosis (panel B).
Eumycetoma patients were significantly more often sero-positive for schistosomiasis when compared to matched controls (p,0.05; Chi square test).
doi:10.1371/journal.pntd.0002241.g002
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find an overall sero-prevalence of schistosomiasis in our study
population of 51%, which is consistent with the earlier reported
variable sero-prevalences for schistosomiasis in Sudan in the New
Halfa and Um Zukra villages in the Gezira and Kassala regions
(Figure 1) (16% and 70%, respectively) [27–29]. Large variations
in prevalence of schistosomiasis even occur among villages in close
proximity and depend on multiple factors, such as the environ-
mental conditions for the intermediate snail host and the hygiene
and bathing habits of the inhabitants [22]. The overall sero-
prevalence of Toxoplasma gondii in our study population was 42%,
which was exactly the same as found by Abdel-Hameed et al. in
Gezira in 1991 [30]. This study now showed that eumycetoma
patients were significantly more often sero-positive for schistoso-
miasis when compared to matched, endemic controls. The
correlation is strengthened by the fact that antibody levels against
Toxoplasma, another prevalent infection in Sudan, did not correlate
with eumycetoma disease. Furthermore no correlation was found
between seropositivity of schistosomiasis and toxoplasmosis.
The main underlying cause may be the strong Th2-response
induced by schistosomiasis and the high expression of interleukin-
10 (IL-10) by Th2 cells [16,31]. IL-10 is capable of inhibiting
synthesis of pro-inflammatory cytokines. Another anti-inflamma-
tory trait of IL-10 is its potent ability to suppress the antigen-
presentation capacity of antigen presenting cells. Increased IL-10
cytokine levels have also been detected in mycetoma lesions [7,32]
as well as in animal models of actinomycetoma caused by Nocardia
brasiliensis [33]. Moreover, IL-10 levels were significantly elevated
in serum of M. mycetomatis eumycetoma patients in Sudan [7],
suggesting that IL-10 concentrations also play an important role in
development or maintenance of eumycetoma.
In conclusion, even among this relatively small number of
patients, eumycetoma was significantly associated with schistoso-
miasis and not with toxoplasmosis. Since this correlation is only
based on serological data, animal studies are currently performed
to investigate the precise role of schistosomiasis and Th2-
predisposition in the development of fungal eumycetoma.
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